Skip to main content
. 2022 Dec 3;23(23):15256. doi: 10.3390/ijms232315256

Figure 3.

Figure 3

Molecular events responsible to MPN onset and evolution. This image summarizes the molecular processes and pathways involved in MPN onset and leukemic evolution described in the main text. Abbreviations: JAK2: Janus Kinase 2; CALR: Calreticulin; TPO-R: Thrombopoietin Receptor; STAT: Signal Transducer and Transcription Activator; PRC2: Polycomb Repressive Complex 2; ASXL1: Additional Sex Combs Like 1; EZH2: Enhancer of Zeste Homolog 2; EED: Polycomb protein EED; SUZ12: Polycomb protein SUZ12; RBBP4/7: Histone-binding protein RBBP4/7; Ac: Acetylation; Me3: three-methylation; H3K27: Histone 3 Lysin 27; DNMT3A: DNA methyltransferase 3 α; TET2: Ten-Eleven-Translocation 2; IDH1/2: Isocitrate Dehydrogenases 1/2; ISO: Isocitrato; α-KG: α-ketoglutarate; 2-HG: 2-Hidroxyglutarate; p53: Tumor Protein 53; SRSF2: Serine/Arginine Rich Splicing Factor 2; SF3B1: Splicing factor 3B subunit 1; U2AF1: Splicing factor U2AF 35 kDa subunit; U2AF1: U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2; RUNX1: Runt-related transcription factor 1; SETBP1: SET binding protein 1; FLT3: FMS-like tyrosine kinase 3; SHP2: SH2 containing protein tyrosine phosphatase-2; Ras: Rat sarcoma virus; Raf: RAF proto-oncogene serine/threonine-protein kinase; MEK: Mitogen-activated protein kinase kinase; ERK: extracellular signal-regulated kinase; STAG2: Stromal Antigen 2; NPM1: Nucleophosmin; PU.1: Transcription factor PU.1. Created with BioRender.com.